What is the Indication of Agalsidase Alfa? An Overview of Its Use in Fabry Disease
•
5 min read
Fabry disease is a rare, X-linked genetic disorder affecting approximately 1 in 40,000 to 60,000 males due to a deficient enzyme. Agalsidase alfa is an enzyme replacement therapy developed to address this deficiency, and its indication is the long-term treatment of Fabry disease by targeting its root cause.
